ARS Pharmaceuticals, Inc. — Director's Dealing 2020

Dec 4, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2020-12-03

Reporting Person: Alexandria Venture Investments, LLC (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A redeemable convertible preferred stock	$		Common stock (384748.0)		Direct
Series B redeemable convertible preferred stock	$		Common stock (314664.0)		Direct

Footnotes

F1: The preferred stock is convertible into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering, for no additional consideration.